Acadia Pharmaceuticals Company Profile (NASDAQ:ACAD)

Analyst Ratings

Consensus Ratings for Acadia Pharmaceuticals (NASDAQ:ACAD) (?)
Ratings Breakdown: 2 Hold Rating(s), 7 Buy Rating(s)
Consensus Rating:Buy (Score: 2.78)
Consensus Price Target: $46.44 (24.05% upside)

Analysts' Ratings History for Acadia Pharmaceuticals (NASDAQ:ACAD)
Show:
DateFirmActionRatingPrice TargetActions
7/26/2016Cowen and CompanyReiterated RatingOutperform$42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/26/2016Needham & Company LLCReiterated RatingBuy$49.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/26/2016Piper Jaffray Cos.Reiterated RatingOverweight$44.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2016Bank of America Corp.DowngradeBuy -> Neutral$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/22/2016Leerink SwannReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/1/2016AegisReiterated RatingBuy$54.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/28/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/22/2016JMP SecuritiesReiterated RatingOutperform$43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/12/2015Jefferies GroupLower Price TargetBuy$50.00 -> $47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/6/2015Roth CapitalReiterated RatingBuy$42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Acadia Pharmaceuticals (NASDAQ:ACAD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q116($0.42)($0.45)$0.22 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q415($0.38)($0.45)$0.02 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.40)($0.39)$0.05 million$0.04 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.33)($0.39)$0.06 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.27)($0.40)$0.09 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2015Q414($0.26)($0.28)$0.08 million$0.05 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q3($0.12)($0.25)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2014Q2($0.17)($0.22)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014Q1($0.13)($0.19)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q4($0.14)($0.13)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2013Q2 2013($0.09)($0.11)$0.45 million$451.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013Q1 2013($0.08)($0.08)$0.45 million$0.42 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2012Q312($0.09)($0.04)$1.90 million$3.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Acadia Pharmaceuticals (NASDAQ:ACAD)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.44)($0.44)($0.44)
Q2 20161($0.46)($0.46)($0.46)
Q3 20161($0.48)($0.48)($0.48)
Q4 20161($0.43)($0.43)($0.43)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Acadia Pharmaceuticals (NASDAQ:ACAD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Acadia Pharmaceuticals (NASDAQ:ACAD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/12/2016Glenn BaityEVPSell16,000$35.00$560,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/11/2016Glenn BaityEVPSell4,057$35.00$141,995.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/18/2016Leslie L IversenDirectorSell33,697$33.53$1,129,860.41View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2016Bros. Advisors Lp BakerDirectorBuy1,449,090$27.08$39,241,357.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2016L.P. 14159DirectorBuy2,586,206$29.00$74,999,974.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2015Leslie L. IversenDirectorSell30,000$36.01$1,080,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2015Michael T BorerDirectorSell27,973$33.02$923,668.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2015Uli HacksellCEOSell30,000$33.98$1,019,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2014Mary Ann GrayDirectorSell12,250$31.74$388,815.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2014Uli HacksellCEOSell30,000$31.00$930,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2014Michael T BorerDirectorSell15,000$30.05$450,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2014Roger MillsCMOSell25,000$30.09$752,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Uli HacksellCEOSell30,000$29.28$878,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2014William Mcdowall WellsDirectorSell5,810$29.00$168,490.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2014Uli HacksellCEOSell30,000$24.15$724,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014Laura BregeDirectorSell10,000$28.07$280,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014William Mcdowall WellsDirectorSell9,190$29.15$267,888.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2014Uli HacksellCEOSell30,000$27.36$820,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Uli HacksellCEOSell15,000$22.89$343,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2014Uli HacksellCEOSell20,000$22.22$444,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Uli HacksellCEOSell20,000$23.10$462,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2014William Mcdowall WellsDirectorSell15,000$23.03$345,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Torsten RasmussenDirectorSell32,857$20.03$658,125.71View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2014Uli HacksellCEOSell25,000$17.75$443,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2014Thomas AasenCFOSell15,000$22.48$337,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2014Torsten RasmussenDirectorSell30,000$21.98$659,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2014Bros. Advisors Lp BakerDirectorBuy526,316$28.50$15,000,006.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2014Glenn BaityVPSell42,000$30.28$1,271,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/1/2013Torsten RasmussenDirectorSell37,692$23.00$866,916.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/1/2013Uli HacksellCEOSell15,000$23.24$348,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2013Laura BregeDirectorSell10,000$21.63$216,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2013Thomas H AasenCFOSell30,000$27.87$836,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/20/2013Roger MillsCMOSell35,965$25.01$899,484.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2013Lester Ph KaplanDirectorSell66,356$22.90$1,519,552.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2013Laura BregeDirectorSell46,153$22.80$1,052,288.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Torsten RasmussenDirectorSell40,000$20.28$811,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2013Mary Ann GrayDirectorSell15,000$20.68$310,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2013Thomas AasenCFOSell60,000$20.15$1,209,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2013Uli HacksellCEOSell52,771$20.14$1,062,807.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2013Felix BakerDirectorBuy2,340,314$14.34$33,560,102.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013Felix BakerDirectorBuy1,993,000$12.50$24,912,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/12/2013Glenn BaityVPSell60,000$12.42$745,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/11/2013Thomas H AasenCFOSell40,000$11.06$442,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Acadia Pharmaceuticals (NASDAQ:ACAD)
DateHeadline
07/27/16 02:18 PMNotable Brokerage Recommendations: Werner Enterprises, Inc. (NASDAQ:WERN), ACADIA Pharmaceuticals Inc ... - Review Fortune
07/27/16 02:18 PMPiper Jaffray Analyst Shows More Confidence In ACADIA Pharmaceuticals Inc. (ACAD) Following Investors Meeting ... - Smarter Analyst
07/26/16 11:38 AMETF’s with exposure to ACADIA Pharmaceuticals, Inc. : July 26, 2016 -
07/25/16 02:16 PMStocks Alert: Medical Properties Trust Inc. (MPW), UDR, Inc. (UDR), ACADIA Pharmaceuticals Inc. (ACAD) - iStreetWire
07/25/16 02:16 PMCowen Weighs In on ACADIA Pharmaceuticals Inc. (ACAD) Following Investors Meeting - Smarter Analyst
07/25/16 07:01 AMSignificant Movements: Endo International plc (NASDAQ:ENDP) , ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Street Updates
07/23/16 02:15 PMStock Up Nicely This Week: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - TGP
07/23/16 02:15 PMIs $60 Price Target Attainable For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)? - Investor Newswire
07/23/16 02:15 PMNeedham Weighs In on ACADIA Pharmaceuticals Inc. (ACAD) Following Meeting With Management - Smarter Analyst
07/23/16 09:41 AMThese 3 Biotechs Have Automatic Demand -
07/22/16 10:25 AMAnalyst Views That Are Worth Watching: QEP Resources Inc (NYSE:QEP), ACADIA Pharmaceuticals Inc. (NASDAQ ... - Review Fortune
07/22/16 07:08 AMACADIA Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACAD-US : July 22, 2016 -
07/21/16 02:15 PMStocks To Watch: ACADIA Pharmaceuticals Inc. (ACAD), Gramercy Property Trust Inc. (GPT), The Gap, Inc. (GPS) - iStreetWire
07/21/16 02:15 PMTwo Buzzers within Analysts Radar: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) , St. Jude Medical, Inc. (NYSE:STJ) - Street Updates
07/21/16 02:15 PMACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Current Analyst Ratings - Fiscal Standard
07/20/16 02:25 PMEarnings Focus and Crowd Sourced Sentiment Review for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - TGP
07/20/16 02:25 PMShares Jumping Higher in Session: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - TGP
07/19/16 02:16 PMCommit To Buy Acadia Pharmaceuticals At $18, Earn 11.4% Using Options
07/18/16 02:15 PMShares of ACADIA Pharmaceuticals (ACAD) Drops by -4.68% - Trade Calls
07/18/16 12:03 PMThis Could Be the Next Big Pharma Buyout -
07/17/16 07:01 AMACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/16/16 02:15 PMAnalyst Target and Average Rating Watch: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Press Telegraph
07/15/16 12:51 PMActive biotech company shares in the news: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Eleven Biotherapeutics ... - The Voice Registrar
07/15/16 12:51 PMNoticeable Insider Trading and Expert's Analysis: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Post Registrar
07/14/16 07:44 PMACADIA Pharmaceuticals Inc. (ACAD) Drops 5.08% on July 13 - Equities.com
07/14/16 11:06 AMBerson Corrado Investment Advisors buys $3534979 stake in ACADIA Pharmaceuticals (ACAD) - Trade Calls
07/14/16 11:06 AMTime To Put On The Watch List? - ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Alexion Pharmaceuticals, Inc ... - The Voice Registrar
07/14/16 11:06 AMACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP AND GC Glenn Baity, Unloaded $560033 in Stock - Consumer Eagle
07/13/16 07:48 PMACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Trading Down – Insider Trading Activity
07/13/16 07:48 PMEVP AND GC of ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), Baity Glenn, sells 4,057 shares worth $142,001
07/13/16 02:16 PM2 Biotech Stocks News And Price Trends: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Juno Therapeutics Inc ... - The Voice Registrar
07/13/16 02:16 PMAcadia Pharmaceuticals: What Is Next For Nuplazid? - Seeking Alpha
07/12/16 08:52 AMAnalyst Recommended Stock: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - News Oracle
07/12/16 08:52 AMOption Market: ACADIA Pharmaceuticals Inc Risk Hits An Elevated Level - CML News
07/11/16 02:15 PMNews Buzz: Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Deltic ... - KC Register
07/11/16 07:03 AMStock Rating Watch and Earnings Insight for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Press Telegraph
07/11/16 07:03 AMCompany Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Rally 1.08% - TheFounders Daily
07/10/16 02:16 PMStock on the Rise for the Quarter: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Engelwood Daily
07/08/16 07:25 PMIs $55 Within Reach For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)? - Investor Newswire
07/08/16 02:16 PMCompany Stock Focus for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Which Way Will Shares Head? - Press Telegraph
07/08/16 02:16 PMACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) at $33.51: How much higher it can go - Review Fortune
07/08/16 02:16 PMACADIA Pharmaceuticals Inc.'s (ACAD) Nuplazid Adoption To Be Slower Than Expectations: Piper Jaffray - TCC
07/06/16 02:15 PMStocks inside Analysts Limelight: Medtronic plc (NYSE:MDT) , ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Street Updates
07/06/16 07:02 AMBiotechnology Stocks Technical Review - Medivation, ACADIA Pharma, Regulus Therapeutics, and - PR Newswire (press release)
07/06/16 07:02 AMBroker Outlook For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Fiscal Standard
07/06/16 07:02 AMACADIA Pharmaceuticals Inc. (ACAD) Jumps 5.51% on July 04 - Equities.com
07/05/16 10:56 AMACADIA Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACAD) : July 5, 2016 -
07/05/16 10:24 AMAcadia Pharmaceuticals Inc.: Why ACAD Stock Will Be Volatile Over the Next Year - <p><a rel="nofollow" href="http://investorplace.com">InvestorPlace</a><a rel="nofollow" href="http://investorplace.com">InvestorPlace - Stock Market News, Stock Advice & Trading Tips</a></p> <p>ACAD may have a rocky year ahead, but long-term any losses or shortcomings for Acadia will prove to be an excellent investment opportunity. </p> <p>The post <a rel="nofollow" href="http://investorplace.com/2016/07/acadia-pharmaceuticals-acad-stock-volatile/">Acadia Pharmaceuticals Inc.: Why ACAD Stock Will Be Volatile Over the Next Year</a> appeared first on <a rel="nofollow" href="http://investorplace.com">InvestorPlace</a>.</p>
07/05/16 07:01 AMHC Stocks Summary: Immunomedics, Inc. (NASDAQ:IMMU), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - share market updates (press release)
07/04/16 07:20 AMACADIA Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACAD-US : July 4, 2016 -

Social

About Acadia Pharmaceuticals

Acadia Pharmaceuticals logoACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system disorders. The Company's lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson's disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist (SSIA), targeting 5-HT2A receptors. The Company's Pimavanserin is a chemical entity, which has completed Phase III development, and is indicated for the treatment of Parkinson's disease psychosis. NUPLAZID (pimavanserin) is a selective serotonin inverse agonist preferentially targeting the 5-HT2A receptor, a key serotonin receptor that plays a role in psychosis. Through this mechanism, NUPLAZID has demonstrated efficacy in Parkinson's disease psychosis in its Phase III pivotal trial and avoids the side effects of existing antipsychotics.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ACAD
  • CUSIP:
Key Metrics:
  • Previous Close: $37.44
  • 50 Day Moving Average: $35.07
  • 200 Day Moving Average: $28.47
  • P/E Ratio: N/A
  • P/E Growth: -0.28
  • Market Cap: $4.24B
  • Beta: 3.45
  • Current Year EPS Consensus Estimate: $-1.74 EPS
  • Next Year EPS Consensus Estimate: $-1.36 EPS
Additional Links:
Acadia Pharmaceuticals (NASDAQ:ACAD) Chart for Thursday, July, 28, 2016